What Are EGFR Bispecific Antibodies and How Do They Work?

EGFR bispecific antibodies are lab-engineered proteins designed to grab two different molecular targets at once, with at least one arm latching onto the epidermal growth factor receptor (EGFR), a protein that sits on cell surfaces and, when it misbehaves, drives the growth of several cancer types. The first EGFR bispecific antibody to reach patients, amivantamab, received accelerated FDA approval in 2021 for a specific form of lung cancer that older EGFR-targeting drugs struggle to treat. What makes these molecules interesting is not just that they hit two targets simultaneously but the cascade of biological consequences that dual binding sets off, from blocking growth signals to flagging cancer cells for immune destruction.

Why EGFR Is Such a Big Deal in Cancer

EGFR is a receptor that normally helps regulate cell growth, division, and repair. When it works correctly, growth signals arrive, the receptor relays them inside the cell, and then it shuts off. In many cancers, that off switch breaks. Mutations, extra copies of the gene, or runaway signaling keep EGFR stuck in the “on” position, telling cells to keep dividing. This plays a major role in non-small cell lung cancer, colorectal cancer, glioblastoma, head and neck cancers, and gastric cancer.¹

For two decades, the standard tools against EGFR have been tyrosine kinase inhibitors (TKIs), which are pills that block the receptor’s internal signaling machinery, and monoclonal antibodies like cetuximab, which stick to the outside of the receptor to shut it down. Both approaches have genuinely improved outcomes for many patients. The problem is resistance. Cancers find workarounds: new mutations in EGFR itself, activation of alternative growth pathways (particularly one involving a receptor called MET), and disruptions to how the receptor is recycled and destroyed inside the cell.¹ Bispecific antibodies emerged partly as an answer to that resistance problem.

What Makes a Bispecific Antibody Different From a Regular One

A conventional therapeutic antibody is symmetrical. Both of its binding arms recognize the same target. A bispecific antibody breaks that symmetry so each arm grabs something different. That sounds like a small engineering change, but it opens up strategies that a single-target antibody simply cannot execute: blocking two receptors at once, pulling an immune cell up against a tumor cell, or forcing two receptors into the same recycling bin inside the cell so both get destroyed together.²

In the case of EGFR bispecific antibodies, one arm targets EGFR and the other targets a second molecule relevant to cancer growth or immune evasion. The identity of that second target varies by drug. The most clinically advanced version, amivantamab, pairs EGFR with MET. Others in development pair EGFR with the immune-cell marker CD3 to recruit T cells, with the HER3 receptor to block signaling crosstalk, with the growth receptor IGF-1R, or with the stem-cell marker LGR5 for use in colorectal cancer.

How Amivantamab Works Step by Step

Amivantamab is the clearest window into how an EGFR bispecific antibody operates, because it has the most clinical data. One arm binds EGFR and the other binds MET, and the drug does several things simultaneously.

First, it blocks ligand binding at both receptors. The EGFR arm prevents epidermal growth factor from activating the receptor, while the MET arm physically blocks HGF (the growth factor that activates MET) from docking. Structural studies show that the antibody’s light chain on the MET side has direct steric clashes with HGF, making it impossible for both the antibody and the growth factor to occupy the receptor at the same time.³ With both growth signals blocked, the downstream pathways that tell the cancer cell to survive and divide get quieter.

Second, it forces both receptors off the cell surface. When amivantamab binds EGFR and MET simultaneously, it triggers the cell to internalize and degrade both receptors at once, a process sometimes called “co-degradation.” The practical effect is that the cancer cell loses the very antennae it depends on for growth signals. Preclinical work with another EGFR-MET bispecific, EMB-01, shows this mechanism clearly: the molecule drives enhanced endocytosis and pulls both EGFR and MET into the cell’s recycling pathway for destruction.⁴

Third, amivantamab recruits the patient’s immune system. The antibody’s Fc region (the tail end, which is not involved in target binding) is recognized by natural killer cells and macrophages, triggering antibody-dependent cellular cytotoxicity (ADCC). In plain terms, the drug acts like a flag: one end holds onto the cancer cell, and the other end waves down immune cells to come kill it.⁵ This immune-directed killing adds a layer of attack that TKIs, which work purely by blocking chemical signals, cannot provide.

Why Targeting EGFR and MET Together Matters for Resistance

One of the most common ways lung cancers escape EGFR-targeted drugs is by cranking up MET signaling instead. When an EGFR inhibitor shuts down one growth pathway, cancer cells with amplified MET can reroute their survival signals through that backup channel. By the time patients develop resistance to osimertinib (the most widely used third-generation EGFR TKI), MET amplification is among the most frequently identified escape mechanisms.⁶

A bispecific antibody that blocks both EGFR and MET simultaneously cuts off the main road and the detour at the same time. That is the core logic behind amivantamab’s design: if the two pathways are interdependent, hitting only one invites the other to compensate.⁷ This reasoning extends beyond MET amplification. Amivantamab has shown preclinical activity against several EGFR mutations that resist older drugs, including the T790M gatekeeper mutation, the C797S mutation that defeats osimertinib, and the exon 20 insertion mutations that most TKIs barely touch.⁸

Clinical Results So Far

Amivantamab first proved itself in patients with EGFR exon 20 insertion mutations, a subgroup that accounts for a small but meaningful fraction of EGFR-mutant lung cancers. These insertions change the shape of the receptor’s kinase domain in a way that makes most TKIs ineffective, leaving patients with few good options after platinum-based chemotherapy fails.

In the initial CHRYSALIS study, among 81 patients with exon 20 insertions who had already been through at least one prior therapy, the response rate was 40%, including three complete responses, with a median duration of response of about 11 months and median progression-free survival of roughly 8 months.⁹ Those numbers earned amivantamab its accelerated FDA approval in May 2021, alongside a companion liquid biopsy diagnostic to identify the insertion mutations from a blood draw.¹⁰

More impressive results followed when amivantamab was combined with standard chemotherapy as a first-line treatment for the same patient population. A randomized trial found that adding amivantamab to chemotherapy nearly doubled median progression-free survival compared with chemotherapy alone: about 11.4 months versus 6.7 months. At 18 months, roughly a third of patients in the combination arm had not yet progressed, compared with just 3% in the chemotherapy-only arm. Response rates also jumped, with about three-quarters of patients in the combination group showing tumor shrinkage versus under half with chemotherapy alone.¹¹

Side Effects and How They Are Managed

The most common side effect of amivantamab by intravenous infusion is an infusion-related reaction (IRR) during the first dose. In the CHRYSALIS study, about two-thirds of patients experienced one, usually presenting as chills, shortness of breath, flushing, nausea, or chest discomfort. The reassuring part: the vast majority of these reactions were mild to moderate, the median time to onset was about an hour into the infusion, and they resolved quickly. Severe reactions (grade 3 or 4) occurred in fewer than ten patients out of 380, and only four patients had to stop treatment entirely because of an IRR.¹² Roughly 90% of all IRRs happened on the very first infusion day and did not recur on subsequent doses.¹³

Skin toxicities are the other major class of side effects, and they are directly tied to the drug’s EGFR-blocking mechanism. EGFR is not only active in tumors; it plays a role in normal skin, hair, and nail biology. Blocking it there leads to predictable problems. In one detailed series of patients on amivantamab monotherapy, every single patient developed acne-like rash and paronychia (painful swelling around the nails). Hair-growth changes, including excess facial hair in women and altered scalp-hair texture, were common. Skin fissures and scalp abrasion also appeared frequently.¹⁴ These are not life-threatening, but they can be distressing. The clinical recommendation is proactive management: starting a tetracycline antibiotic, intensive moisturizing, and careful nail hygiene before treatment begins, not waiting until problems appear. Biopsies of unusual skin reactions have shown excessive granulation tissue, which researchers link to EGFR inhibition disrupting how skin cells grow and differentiate.¹⁵

The Subcutaneous Formulation Changes the Patient Experience

Intravenous amivantamab requires long infusion times, particularly early on. The first dose is split over two days, with initial infusions lasting around five hours. This is partly a safety measure to manage IRR risk. By later cycles the infusion shortens to about two hours, but the process still ties patients to infusion chairs regularly.

A subcutaneous formulation, injected under the skin in under ten minutes, was developed to address this. In the PALOMA-3 trial, which compared subcutaneous and intravenous amivantamab (both combined with the TKI lazertinib), response rates were similar between the two routes, and the subcutaneous group actually had longer overall survival. The practical advantages were stark: IRRs dropped from about two-thirds of patients on IV to 13% on subcutaneous, venous blood clots were less common, and the split-dose first infusion was no longer needed.¹⁶ The phase Ib study that established the subcutaneous doses confirmed administration times of ten minutes or less, compared to over two hours for intravenous delivery beyond the first few cycles.¹⁷ For a patient who may be on treatment for months or years, this difference in chair time and reaction risk matters enormously to quality of life.

How These Molecules Are Built

Making a bispecific antibody is harder than it sounds. If you simply mix the two halves of two different antibodies in a cell, the heavy chains pair up randomly, giving you a mess of mismatched molecules. Only a fraction will have the desired one-arm-for-each-target configuration. Early bispecific antibody programs were hampered by manufacturing yields in the low single digits.

The breakthrough that made modern bispecific antibodies practical is called “knobs-into-holes” engineering. One heavy chain gets a bulky amino acid swapped in at a specific position (creating a “knob”), while the other heavy chain gets a small amino acid substituted at the corresponding spot (creating a “hole”). The knob fits into the hole, strongly favoring the pairing of one chain with the other rather than two identical chains linking up. When this approach was first described, the correctly paired bispecific heterodimer made up roughly 92% of the purified protein, compared to the low yields of unengineered systems.¹⁸ This technology has been used to manufacture multiple bispecific antibodies now in clinical use or development.¹⁹

Beyond Amivantamab and the EGFR-MET Pairing

While amivantamab is the furthest along, researchers are exploring EGFR bispecific antibodies with very different second targets, each designed to exploit a different vulnerability.

One approach pairs EGFR with HER3, a closely related receptor that cancer cells often lean on when EGFR itself is blocked. An early bispecific called DL11f was shown to work by physically preventing both EGFR and HER3 from adopting the shapes they need to activate, essentially locking both receptors in their “off” conformations and disrupting the crosstalk between them.²⁰

Another line of work pairs EGFR with IGF-1R, the receptor for insulin-like growth factor. Tetravalent (four-armed) antibodies targeting both receptors have been engineered that not only block signaling through both pathways but also force strong downregulation of IGF-1R from the cell surface while enhancing EGFR degradation beyond what a single-target EGFR antibody could achieve.²¹

A particularly creative strategy targets EGFR alongside LGR5, a stem-cell marker enriched on cancer stem cells in colorectal tumors. The bispecific antibody itself does not kill; instead, it is coupled to a toxic drug payload as an antibody-drug conjugate (ADC). What makes this pairing clever is that LGR5 is constitutively internalized by the cell, meaning it is constantly being pulled inside. The bispecific antibody hitches EGFR to that conveyor belt, dragging both receptors into the cell’s lysosomes for destruction and delivering the toxic payload deep inside the cell at the same time. In colorectal cancer cell lines, this “hijacking” of LGR5 internalization drove significantly more EGFR degradation than either a standalone EGFR antibody or an LGR5-targeting one could manage alone.²²

Then there are T-cell engagers, bispecific antibodies where the second arm grabs CD3 on T cells rather than a second tumor-associated receptor. Instead of passively flagging cancer cells for immune detection, these molecules physically bridge a T cell to an EGFR-expressing tumor cell, forcing an immune attack even if the patient’s immune system has learned to ignore the cancer. One such EGFR-CD3 engager, BC3448, is being explored in combination with an immune-boosting agent and an epigenetic drug to try to overcome resistance even in lung cancers that have failed third-generation TKIs.²³

Activity in Brain Metastases

One of the biggest challenges with any antibody therapy is getting it into the brain. Antibodies are large molecules, and the blood-brain barrier is designed to keep large molecules out. For lung cancer patients with brain metastases or leptomeningeal disease (cancer spreading along the membranes that coat the brain and spinal cord), treatment options have historically been limited to radiation and TKIs that can cross the barrier.

There is emerging case-report evidence that amivantamab can produce durable responses even in leptomeningeal disease after osimertinib failure, including at least one reported complete response in a patient with a rare EGFR mutation.²⁴ This is preliminary, and a single case report does not establish a treatment standard. But it challenges the assumption that antibody therapies are inherently useless against CNS disease, and larger studies are actively looking at how well amivantamab performs when cancer has spread to the brain. If the effect holds up, it would expand the clinical utility of EGFR bispecific antibodies into territory that has been extremely difficult to treat.